

PRIOR AUTHORIZATION REQUEST FORM

EOC ID:

Stelara (Ustekinumab)

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name: Supervising Physician:		
Member/Subscriber Number:	Fax:	Phone:	
Date of Birth:	Office Contact:		
Group Number:	NPI:	State Lic ID:	
Address:	Address:		
City, State ZIP:	City, State ZIP:		
Primary Phone:	Specialty/facility name (if applicable)	:	
Drug Name and Strength:			
Directions / SIG:			
Please attach any pertinent medical history or information for this patient that may support approval. Please answer the following questions and sign.			
Q1. Select the regimen being requested.			
☐ Stelara 90 mg SubQ every 8 weeks			
Stelara 90 mg SubQ every 12 weeks			
Stelara 45 mg SubQ every 12 weeks			
☐ IV Induction: 260 mg			
☐ IV Induction: 390 mg			
☐ IV Induction: 520 mg			
☐ Other			
Q2. What diagnosis is this drug being prescribed for (select ALL that apply)?			
☐ Plaque psoriasis ☐ Psoriatic arthritis	☐ Crohn's Disease	Other	
Q3. Provide ICD code(s) for diagnosis.			
Q4. Please indicate location of administration.			
☐ Home			
☐ Physician office (drug from office stock - buy and bill)			
☐ Physician office (MEMBER to obtain drug from PHARMACY with a prescription)			



PRIOR AUTHORIZATION REQUEST FORM EOC ID:

Stelara (Ustekinumab)

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name: Supervising Physician:	
☐ Other		
Q5. What is the prescriber's specialty? ☐ Dermatologist ☐ Rheumatologist	☐ Gastroenterology ☐ Other	
Q6. Select ALL of the following that apply to the patient: Moderate to severe PLAQUE PSORIASIS affecting GREATER THAN 5% of body surface area (BSA) Moderate to severe PLAQUE PSORIASIS affecting CRUCIAL BODY AREAS such as hands, feet, face, or genitals PSORIATIC ARTHRITIS with documented SPINAL INVOLVEMENT (psoriatic spondylitis) None of the above		
Q7. Has the patient failed at least TWO TOPICAL treatments [including but not limited to corticosteroids, Vitamin D analogues, Vitamin D analogue/corticosteroid combinations, Tazorac® (tazarotene)]? Yes No No N/A - Patient does not have plaque psoriasis		
Q8. Has the patient failed, or does the patient have a contraindication to phototherapy (UVB or PUVA)? Yes No N/A - Patient does not have plaque psoriasis		
Q9. Select ALL of the following that apply to this patient: For psoriasis, failed AT LEAST ONE of the following: methotrexate, cyclosporine, acitretin, leflunomide, sulfasalazine, tacrolimus For psoriasis, contraindication to methotrexate, cyclosporine, acitretin, leflunomide, sulfasalazine, or tacrolimus For psoriatic arthritis, failed methotrexate For psoriatic arthritis, contraindication to methotrexate For psoriatic arthritis, failed AT LEAST ONE of the following: sulfasalazine, leflunomide, cyclosporine, acitretin, tacrolimus For psoriatic arthritis, contraindication to sulfasalazine, leflunomide, cyclosporine, acitretin, tacrolimus For Crohn's Disease, failure of or contraindication to an anti-inflammatory drug (e.g. mesalamine, sulfasalazine), corticosteroid, or an immunosuppressive		
Q10. Is the patient a NEW START to Stelara?		



PRIOR AUTHORIZATION REQUEST FORM EOC ID:

Stelara (Ustekinumab)

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

	Prescriber Name:
Patient Name:	Supervising Physician:
☐ Yes ☐ No	
Q11. Select the agents the patient has failed Enbrel Humira Other (please specify) None	
Q12. Has the patient failed Cosentyx?	
Q13. What is the patient's weight? Less than or equal to 55 kg (121 lbs) 55 to 85 kg (121 to 187 lbs) 86 to 100 kg (189 to 220 lbs) Greater than 100 kg (220 lbs)	
Q14. For continuation of Stelara for Crohn's disease, is th dose? [Please submit clinical documentation]	ere documentation of clinical response from the IV initiation
☐ Yes ☐ No	
Q15. Additional Comments	
Prescriber Signature	Date

□ Expedited/Urgent - By checking this box and signing above, I certify that applying the standard review timeframe may seriously jeopardize the life or health of the enrollee or the enrollee's ability to regain maximum function



PRIOR AUTHORIZATION REQUEST FORM EOC ID: Stelara (Ustekinumab)

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

	Prescriber Name:	
Patient Name:	Supervising Physician:	
Lack of the necessary documentation may result in a medical necessity denial. Requesting providers may speak to the SWHP medical		

Lack of the necessary documentation may result in a medical necessity denial. Requesting providers may speak to the SWHP medical director at 1-888-316-7947 regarding the case to have an opportunity to help impact the decision on a request before coverage has been decided.

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document